Objective: To document the incidence of venous thromboembolism in Guillain–Barré syndrome and current practice of anticoagulating these patients.
Design: Retrospective study.
Setting: Acute neurology and rehabilitation wards in a teaching hospital.
Subjects: Seventy-three patients with Guillain–Barré syndrome admitted to Addenbrooke's Hospital from 1995 to 1999.
Results: Out of 73 patients, 50 were anticoagulated (68%) for 5–490 days with mean of 72 days. Anticoagulation was discontinued in 28 patients when they could walk independently and in six who were still wheelchair dependent. Five patients developed clinical deep venous thrombosis (DVT) (7%), three of them had pulmonary emboli. Venous thrombosis occurred in the ”rst two months after onset in four patients. Two patients were not anticoagulated when they developed their DVT and the other three were on enoxaparin; one of these three had a pulmonary embolism and died. Conclusion: Despite prophylactic anticoagulants being used in the majority of patients admitted with major problems of mobility, 6% (3 out of 50) still developed clinically detected DVT and two developed pulmonary embolism. While this incidence is considerably lower than data reported before routine anticoagulation became a standard practice, these data reinforce the need for anticoagulation and suggest that full anticoagulation might be needed to reduce the incidence of thromboembolic complications further.
Get full access to this article
View all access options for this article.
References
1.
Dismuke SE, Wagner EH. Pulmonary embolism as a cause of death. The changing mortality in hospitalized patients. JAMA1986; 255: 2039-2039.
2.
Seifert J, Stoephasius J, Probst et al. Blood ‘ ow in muscles of paraplegic patients under various conditions measured by a double isotope technique. Paraplegia1972; 10: 185–191.
3.
Weingarden SI. Deep venous thrombosis in spinal cord injury. Overview of the problem. Chest1992; 102(suppl): 6365-6365.
4.
Rentsch HP. Thromboembolische komplikationen nach akuter Hemiplegien. Schweiz Med Wochenschr1987; 117: 1853-1853.
5.
Cope C, Reyes TM, Skversky NJ. Phlebographic analysis of the incidence of thrombosis in hemiplegia. Radiology1973; 109: 58-58.
6.
Gareth PJ. Guillain–Barré syndrome. New York: Thieme Medical Publishers, 1993.
7.
Ropper AH. The Guillain–Barré syndrome. N Engl J Med1992; 326(17): 1130–1137.
Leese J.Thrombotic complications in acute polyneuritis. BMJ1976; 1: 585-585.
10.
Bredin CP. Thrombotic complications in acute polyneuritis. BMJ1976; 1: 837-837.
11.
Hewer RL, Hilton PJ, Crampton Smith A, Spalding JMK. Acute polyneuritis requiring arti” cial respiration. Q J Med1966; 33: 479–491.
12.
Turpie AG, Levine MN, Hirsh J et al. A doubleblind randomised trial of ORG 10172 low molecular weight heparinoid in the prevention of deep venous thrombosis in thrombotic stroke. Lancet1987; I: 523–526.
13.
Prins MH, den Ottolander GJH, Gelsema R et al. Deep vein thrombosis prophylaxis with a low molecular weight heparin in stroke patients (abstract). Thromb Haemost1987; 58 (suppl): 117-117.
14.
Green D, Chen D, Chmiel JS et al. Prevention of thromboembolism in spinal cord injury: Role of low molecular weight heparin. Arch Phys Med Rehabil1994; 75: 290-290.
15.
Green D, Rossi EC, Yao JST et al. Deep venous thrombosis in spinal cord injury: Effect of prophylaxis with calf compression, aspirin and dipiridamole. Paraplegia1982; 20: 22-22.
